论文部分内容阅读
[目的]探讨miRNA-22在不同分期浆液性卵巢腺癌的表达以及与化疗耐药性关系。[方法 ]使用基因芯片技术筛选出差异化表达的miRNA,再用实时荧光定量聚合酶链反应(RT-PCR)检测miRNA-22在人卵巢癌细胞株(SKOV3)、紫杉醇稳定耐药卵巢浆液性囊腺癌细胞亚株(SKOV3-TR30)、人正常卵巢上皮细胞株(IOSE80)及50例确诊为浆液性卵巢腺癌的患者、25例正常人血清中的表达水平,并分析其与患者临床分期的关系以及用药前后的关系。[结果]miRNA-22在SKOV3-TR30耐药株中的表达明显高于SKOV3敏感株中的表达水平(P<0.05),IOSE80正常卵巢上皮细胞株中miRNA-22的表达水平明显低于SKOV3敏感株(P<0.05);在FIGO手术病理不同分期中的表达,Ⅰ、Ⅱ、Ⅲ、Ⅳ期表达水平依次增高;经统一的化疗方案治疗后,化疗无效组的表达水平高于化疗有效组的表达水平(P<0.05)。[结论]miRNA-22可能是卵巢癌患者潜在的肿瘤标志物,miRNA-22的高表达可能与癌细胞的过度增殖与转移、侵袭有关,具有癌基因与抑癌基因的双侧作用,且可能与化疗药物的耐药性密切相关。
[Objective] To investigate the expression of miRNA-22 in serous ovarian adenocarcinoma and its relationship with chemoresistance. [Method] The differentially expressed miRNAs were screened by gene chip technique. The miRNA-22 was detected by real-time fluorescence quantitative polymerase chain reaction (RT-PCR) in human ovarian cancer cell line SKOV3, paclitaxel-resistant ovarian serous (SKOV3-TR30), human normal ovarian epithelial cell line (IOSE80) and 50 cases of diagnosed as serous ovarian adenocarcinoma, 25 cases of normal human serum levels, and analysis of the clinical Staging and the relationship between medication before and after. [Results] The expression of miRNA-22 in SKOV3-TR30 resistant strains was significantly higher than that in SKOV3-sensitive strains (P <0.05). The expression level of miRNA-22 in IOSE80 normal ovarian epithelial cells was significantly lower than that of SKOV3 (P <0.05). The expression levels in stages I, II, III and IV were increased in different stages of FIGO surgical pathology. The expression level of chemotherapy ineffective group was higher than that of chemotherapy effective group Expression level (P <0.05). [Conclusion] miRNA-22 may be a potential tumor marker in patients with ovarian cancer. The overexpression of miRNA-22 may be related to the excessive proliferation, metastasis and invasion of cancer cells, with the bilateral effects of oncogenes and tumor suppressor genes, and may And chemotherapy drug resistance are closely related.